Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$4.91 USD
+0.04 (0.82%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.90 -0.01 (-0.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AUPH 4.91 +0.04(0.82%)
Will AUPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
Other News for AUPH
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals to Present at Investor Conference
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
Aurinia Pharmaceuticals Announces Q1 Results Date